Treatment-resistant depression (TRD) — the patient population failing two or more antidepressant trials representing 30% of major depression cases and the primary target for first-generation psychedelic therapies — creates the most commercially dynamic market segment, with the Psychedelic Medicine Market reflecting TRD as the premium growth commercial driver.

The NIH epidemiological data — 21% of US adults living with depression or anxiety disorders, with approximately 2.8 million having treatment-resistant depression — demonstrates the massive unmet need. Compass Pathways' COMP360 psilocybin achieving statistically significant primary endpoints in both pivotal Phase 3 trials (COMP005 June 2025, COMP006 February 2026) validates the clinical efficacy, with FDA NDA submission expected Q4 2026 and potential approval as the first classic psychedelic medicine.

Rapid onset mechanism — the single-dose psilocybin inducing antidepressant effects within 24 hours versus 6-8 weeks for SSRIs — creates the pharmacological differentiation. Neuroplasticity enhancement through 5-HT2A receptor agonism demonstrating sustained remission at 12 weeks post-single-dose challenges the chronic daily dosing paradigm of traditional antidepressants, with potential for quarterly or biannual maintenance dosing reducing treatment burden.

Healthcare cost offset — the TRD population consuming $15,000-30,000 annually in failed medication trials, hospitalizations, and disability versus $5,000-15,000 per psychedelic treatment course — creates the pharmacoeconomic argument. Employer health plans and Medicaid programs evaluating psychedelic therapy coverage demonstrate the payer interest, with early adopters reporting 40% reduction in depression-related disability claims.

Do you think single-dose or intermittent psychedelic therapy will replace daily antidepressants for TRD, or will it complement existing medications as a rescue therapy for acute decompensation?

What defines treatment-resistant depression, and how common is it? TRD definition and epidemiology: clinical definition (failure to achieve remission after two or more adequate antidepressant trials of different classes, each ≥6 weeks at therapeutic dose, confirmed by structured assessment); prevalence (30% of major depression patients, approximately 2.8 million in US, 100 million globally); economic burden ($15,000-30,000 per patient annually in direct and indirect costs, highest healthcare utilization among psychiatric conditions); risk factors (comorbid anxiety, childhood trauma, chronic medical conditions, bipolar spectrum, personality disorders); current treatment options (augmentation strategies: lithium, thyroid hormone, atypical antipsychotics; ECT: 50-60% remission but cognitive side effects, stigma; TMS: 30-40% response, 4-6 week course; VNS: invasive, limited efficacy); psychedelic opportunity (single-dose rapid onset, 60-70% remission, sustained 12+ weeks, neuroplasticity mechanism, reduced treatment burden).

What is the mechanism of psilocybin in treating depression? Neurobiological mechanism: 5-HT2A receptor agonism (primary target, highly expressed in prefrontal cortex, reduced in depression); neuroplasticity enhancement (increased dendritic spine density, synaptogenesis, BDNF upregulation, "reset" of rigid neural circuits); default mode network modulation (reduced DMN connectivity, decreased rumination and self-referential thinking, increased cognitive flexibility); emotional processing (enhanced amygdala response to emotional stimuli, improved fear extinction, increased emotional openness); mystical experience correlation (sense of unity, transcendence, meaningfulness — predicts therapeutic outcomes, not merely side effect); anti-inflammatory effects (reduced pro-inflammatory cytokines, neuroimmune modulation); duration: acute effects 4-6 hours, antidepressant onset 24 hours, peak effect 1-2 weeks, sustained remission 3-6 months; dosing: 10-25mg psilocybin with psychological support, single or intermittent dosing.